| Aim:To investigate the effective potential of Pentoxifylline on immunologic abnormality in patients with Chronic heart failure.Methods: Peripheral blood mononuclear cells were collected from 35 patients with CHF and 10 healthy volunteers (Control group). In vivo, 35 CHF patients were randomized received routine therapy (including diuretic, digitaloid drugs,ACEI, ?-blocker, aldosterone inhibiter )without PTX ( CHF-A,n=20) or with PTX(PTX,400mg,tid ,po) (CHF-B,n=15) for 1 week, both avoid use of immunosuppressive agent. Cytokine-producing Th lymphocytes were quantified by 3-color flow cytometry and anti-CD4, anti-interferon (IFN)-γ, and anti-IL10 mAbs.Results: The ratio of IFN-γ-producing Th1 cells was significant higher ((19.34±6.20)%), and the radio of IL-10-producing Th2 cells was lower ((11.90±5.65)%) in CHF-A group than those of Control group ((7.31±1.42)%, (39.35±3.58)%, respectively, both P<0.05). After the treatment of PTX for 1 week, the radio of IFN-γ-producing Th1 cells was significant lower in CHF-B group ((12.02±3.61)% ) than those of CHF-A group ((15.31±4.22)%,P<0.05).Conclusion: There was a Th1/Th2 cytokine imbalance in patients with CHF.PTX can regulate the polarization of Th1 /Th2 and reduce Th1 immune response in patients with CHF. PTX has broad-spectrum immunomodulatory mechanism. |
